Abstract： Objective To systematically evaluate the efficacy and safety of Chinese medicine combined with nucleoside(acid)analogues in the treatment of chronic hepatitis B.Methods The randomized,double-blind,controlled trials(RCTs)of Chinese medicine combined with nucleoside(acid)analogues in the treatment of chronic hepatitis B in the online database of China knowledge Network(CNKI),Wanfang database,China VIP database,and China biomedical literature database(CBM),EM-BASE,PubMed,Cochrane library were searched.Eleven randomized,double-blind,controlled,clinical trials were included.A total of 2752 patients with chronic hepatitis B were recruited.1376 cases in the Chinese medicine combined with nucleoside(acid)analogues treatment group(trial group)and 1376 cases in the nucleoside(acid)analogues treatment group(control group).Results The results of meta-analysis showed that HBeAg negative conversion rate、HBeAg seroconversion rate,and HBsAg negative conversion rate of the trial group were higher than that in the control group at the end of treatment(≥48 weeks).The Jiedu formulation group showed a greater undetectable HBV-DNA and ALT normalization rate at the end of 24 weeks treatment compared with the control group.There was no statistical difference on the undetectable HBV-DNA,ALT normalization rate,histological improvement(inflammation grade or fibrosis stage)and side effects at the end of treatment(≥48 weeks)between the trial group and the control group.Conclusion The therapy of Chinese medicine combined with nucleoside(acid)analogues was more effective than nucleoside(acid)analogs monotherapy in CHB treatment,and did not increase adverse drug reactions.